rilzabrutinib

Sanofi looks to advance CSU drug rilzabrutinib in Phase III trial
Clinical Trials Arena
Mon, 02/26/24 - 10:35 am
Sanofi
rilzabrutinib
chronic spontaneous urticaria
clinical trials
Sanofi’s Principia purchase fails its first test
EP Vantage
Thu, 09/9/21 - 10:53 am
Sanofi
rilzabrutinib
Principia Biopharma
clinical trials
pemphigus vulgaris
Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia
Pharmaceutical Business Review
Thu, 11/19/20 - 10:40 am
rilzabrutinib
fast track
FDA
Sanofi
Principia Biopharma
chronic immune thrombocytopenia